EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

Hanny Al-Samkari iD, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J Kuter und 1 weitere

New England Journal of Medicine · 12.03.2026 · 394 (11) · 1061-1073

DOI: 10.1056/nejmoa2511882 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 12.03.2026. Verfasst von Hanny Al-Samkari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms, Receptors, Fc, Recombinant Fusion Proteins. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsGastrointestinal NeoplasmsReceptors, FcRecombinant Fusion ProteinsThrombocytopeniaThrombopoietinAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodOxaliplatinPlatelet CountReceptors, ThrombopoietinNeoplasm StagingNauseaHeadacheThromboembolismTreatment OutcomeAged, 80 and over

Substanzen

OxaliplatinReceptors, FcReceptors, ThrombopoietinRecombinant Fusion ProteinsromiplostimThrombopoietin

Autor:innen und Institutionen

  • Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston.
  • Medical Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid.
  • Facultad HM de Ciencias de la Salud de la Universidad Camilo José Cela, Madrid.
  • Instituto de Investigación Sanitaria HM Hospitales, Madrid.
  • Department of Medical Oncology, Gaziosmanpaşa Medical Park Hospital, Istanbul, Turkey.
  • Department of Internal Medicine, İstinye University Faculty of Medicine, Istanbul, Turkey.

ORCID-Profile: Hanny Al-Samkari

Förderung

  • Amgen

Zitieren

APA

Al-Samkari, H., Muñoz, C., Geredeli, Ç., Korantzis, I., González Astorga, B., Arslan, C., Cordeiro Camargo, J. F., Scotté, F., Borges, G., Wang, K., Eisen, M., Kuter, D. J., & Soff, G. A. (2026). Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. New England Journal of Medicine, 394(11), 1061-1073. https://doi.org/10.1056/nejmoa2511882

Vancouver

Al-Samkari H, Muñoz C, Geredeli Ç, Korantzis I, González Astorga B, Arslan C, et al. Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia. New England Journal of Medicine. 2026;394(11):1061-1073. doi:10.1056/nejmoa2511882

BibTeX
@article{AlSamkari2026,
  author = {Al-Samkari, Hanny and Muñoz, César and Geredeli, Çağlayan and Korantzis, Ippokratis and González Astorga, Beatriz and Arslan, Cagatay and Cordeiro Camargo, Johnny Francisco and Scotté, Florian and Borges, Giuliano and Wang, Kejia and Eisen, Melissa and Kuter, David J and Soff, Gerald A},
  title = {Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {11},
  pages = {1061--1073},
  doi = {10.1056/nejmoa2511882}
}
Kostenlos starten →